<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01051310</url>
  </required_header>
  <id_info>
    <org_study_id>COR-2007-03</org_study_id>
    <nct_id>NCT01051310</nct_id>
  </id_info>
  <brief_title>Medtronic CoreValve REDO Study</brief_title>
  <acronym>REDO</acronym>
  <official_title>Feasibility Study of Percutaneous Aortic Valve Implantation With the Medtronic CoreValve System for Percutaneous Aortic Valve Replacement (PAVR) in Patients With a Failing Previously Surgically Implanted Aortic Bioprosthesis and Presenting a High Risk for Repeat Surgical Valve Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed investigation is a prospective, multicenter, non-randomized study to evaluate&#xD;
      the immediate benefits (at discharge and at 30 days) in terms of performance and safety of&#xD;
      the implantation of the Medtronic CoreValve PAV in a failing aortic bioprosthesis. In&#xD;
      addition, the study aims to evaluate the performance and the safety of the implantation of&#xD;
      the Medtronic CoreValve PAV in a failing aortic bioprosthesis at subsequent annual follow-ups&#xD;
      out to 48 months post procedure.&#xD;
&#xD;
      These objectives will be achieved through the following endpoints:&#xD;
&#xD;
        -  Primary safety endpoint - Composite of Major Adverse Events&#xD;
&#xD;
        -  Primary performance endpoint - Technical and procedural success at discharge&#xD;
&#xD;
      Patient Population: Eligible subjects will be at least 75 years old, presenting with a&#xD;
      failing aortic bioprosthesis (stenotic, incompetent or mixed) including homograft or stented&#xD;
      or stentless heterograft, considered poor surgical candidates and necessitating repeat aortic&#xD;
      valve replacement. Up to 20 patients will be included in up to four hospitals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of MAE Free Subjects</measure>
    <time_frame>30 days post-procedure</time_frame>
    <description>Percentage of subjects without a composite major adverse event (MAE) at 30 days post procedure. the composite MAE includes:&#xD;
MACCE (Major Adverse Cardiac or Cerebral Event): cardiac death, documented Mobitz type II second degree and third degree atrioventricular block, neurological events and surgical aortic valve replacement.&#xD;
MAE: non cardiac death including sudden unexpected or unexplained death, cardiac tamponade, nonstructural valve dysfunction resulting in stenosis or regurgitation at the study valve not intrinsic to the valve itself, structural valve deterioration cardiogenic shock, operated valve endocarditis, valve thrombosis, aortic dissection/perforation, major bleeding event, peripheral embolic event and emergent revascularization procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Technical Success.</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>The number of subjects in whom technical success was achieved where technical success was defined based on the device functionality as judged by the investigator adressing the ability of the system (1) to access the failing bioprosthetic valve via a peripheral vessel with the delivery catheter and (2) to deploy the valve accurately across the failing bioprosthetic valve and (3) to remove intact delivery system.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>CoreValve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic CoreValve System</intervention_name>
    <description>Transcatheter Aortic Valve</description>
    <arm_group_label>CoreValve</arm_group_label>
    <other_name>Medtronic CoreValve Transcatheter aortic valve</other_name>
    <other_name>Medtronic CoreValve Percutaneous aortic valve</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 74 years old,&#xD;
&#xD;
          -  Symptomatic failing bioprosthetic aortic valve (stenotic, incompetent or mixed)&#xD;
             confirmed by Doppler echocardiography,&#xD;
&#xD;
          -  Logistic EuroSCORE &gt; 15%, or&#xD;
&#xD;
          -  Any of the following criteria:&#xD;
&#xD;
               1. Left ventricular ejection fraction (LVEF) &lt; 20%,&#xD;
&#xD;
               2. Creatinine clearance &lt; 20mL/min (estimation using the Cockcroft calculation),&#xD;
&#xD;
               3. Renal failure requiring dialysis,&#xD;
&#xD;
               4. Permanent and long lasting (&gt; 6 month duration) atrial fibrillation,&#xD;
&#xD;
               5. Cirrhosis of the liver (Child class A or B),&#xD;
&#xD;
               6. Respiratory impairment (FEV1 &lt; 1L),&#xD;
&#xD;
               7. Previous cardiac surgery (i.e., CABG especially if patient had competent mammary&#xD;
                  arteries on left anterior descending (LAD) artery or occluded saphenous veins&#xD;
                  with high-risk of coronary embolism during re-operation),&#xD;
&#xD;
               8. Pulmonary hypertension ³ 60mmHg,&#xD;
&#xD;
               9. Recurrent pulmonary embolus,&#xD;
&#xD;
              10. Moderate tricuspid (&lt; grade 2+) insufficiency,&#xD;
&#xD;
              11. Any severe disease contraindicating surgery,&#xD;
&#xD;
              12. Calcified aorta (porcelain aorta),&#xD;
&#xD;
              13. Recent myocardial infarction (less than 30 days at baseline),&#xD;
&#xD;
              14. Contraindication for cardiopulmonary bypass,&#xD;
&#xD;
          -  Inner diameter of the failing bioprosthetic aortic valve (homograft or stented or&#xD;
             stentless heterograft) of ³ 19mm and &lt; 26mm as determined by Doppler echocardiography,&#xD;
&#xD;
          -  Signed informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine and&#xD;
             clopidogrel, Nitinol, or sensitivity to contrast media which cannot be pre-medicated,&#xD;
&#xD;
          -  Active infection or endocarditis,&#xD;
&#xD;
          -  Any intra left ventricular mass, thrombus or vegetation evidenced by Doppler&#xD;
             echocardiography,&#xD;
&#xD;
          -  Mitral or tricuspid valvular insufficiency ³ grade 2+,&#xD;
&#xD;
          -  Prosthetic mitral or tricuspid valve,&#xD;
&#xD;
          -  Femoral and/or iliac and/or aortic vascular condition (stenosis, occlusion or&#xD;
             tortuosity) that could complicate endovascular access to the aortic valve&#xD;
             bioprosthesis,&#xD;
&#xD;
          -  Symptomatic carotid or vertebral artery narrowing (&gt; 70%) disease,&#xD;
&#xD;
          -  Aortic abdominal or thoracic aneurysm,&#xD;
&#xD;
          -  Bleeding diathesis or coagulopathy, or patient refuses blood transfusion,&#xD;
&#xD;
          -  Active peptic ulcer or has had upper gastrointestinal bleeding within the past 3&#xD;
             months before baseline,&#xD;
&#xD;
          -  Moribund status or cachexia with short life-expectancy independent of cardiac&#xD;
             condition,&#xD;
&#xD;
          -  Any acute neurological event or dysfunction occurred in the past 6 weeks before&#xD;
             baseline or patient with severe senile dementia,&#xD;
&#xD;
          -  Therapeutic invasive cardiac procedure, other than balloon aortic valvuloplasty,&#xD;
             performed within 30 days prior to study procedure or to be performed during or within&#xD;
             30 days after the study procedure,&#xD;
&#xD;
          -  Currently, enrolled in this study or another investigational drug or device study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Grube, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helios Heart Center Siegburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G. Schuler, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitat Leipzig Herzzentrum, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. Lange, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Munich, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P. de Jaegere, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC Rotterdam, Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.medtronic.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 15, 2010</study_first_submitted>
  <study_first_submitted_qc>January 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2010</study_first_posted>
  <results_first_submitted>October 27, 2017</results_first_submitted>
  <results_first_submitted_qc>August 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 31, 2019</results_first_posted>
  <last_update_submitted>August 20, 2018</last_update_submitted>
  <last_update_submitted_qc>August 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Three sites in Germany enrolled 18 patients between June 2008 and January 2010.</recruitment_details>
      <pre_assignment_details>All 18 subjects signed and informed consent and were admitted to the catheterization laboratory for an attempted implantation. All 18 subjects were subsequently implanted with the CoreValve device.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>All enrolled subjects who received the Medtronic CoreValve aortic valve prosthesis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled subjects who received the Medtronic CoreValve aortic valve prosthesis</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>All enrolled subjects who received the Medtronic CoreValve aortic valve prosthesis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of MAE Free Subjects</title>
        <description>Percentage of subjects without a composite major adverse event (MAE) at 30 days post procedure. the composite MAE includes:&#xD;
MACCE (Major Adverse Cardiac or Cerebral Event): cardiac death, documented Mobitz type II second degree and third degree atrioventricular block, neurological events and surgical aortic valve replacement.&#xD;
MAE: non cardiac death including sudden unexpected or unexplained death, cardiac tamponade, nonstructural valve dysfunction resulting in stenosis or regurgitation at the study valve not intrinsic to the valve itself, structural valve deterioration cardiogenic shock, operated valve endocarditis, valve thrombosis, aortic dissection/perforation, major bleeding event, peripheral embolic event and emergent revascularization procedure.</description>
        <time_frame>30 days post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>All enrolled subjects who received the Medtronic CoreValve aortic valve prosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of MAE Free Subjects</title>
          <description>Percentage of subjects without a composite major adverse event (MAE) at 30 days post procedure. the composite MAE includes:&#xD;
MACCE (Major Adverse Cardiac or Cerebral Event): cardiac death, documented Mobitz type II second degree and third degree atrioventricular block, neurological events and surgical aortic valve replacement.&#xD;
MAE: non cardiac death including sudden unexpected or unexplained death, cardiac tamponade, nonstructural valve dysfunction resulting in stenosis or regurgitation at the study valve not intrinsic to the valve itself, structural valve deterioration cardiogenic shock, operated valve endocarditis, valve thrombosis, aortic dissection/perforation, major bleeding event, peripheral embolic event and emergent revascularization procedure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Technical Success.</title>
        <description>The number of subjects in whom technical success was achieved where technical success was defined based on the device functionality as judged by the investigator adressing the ability of the system (1) to access the failing bioprosthetic valve via a peripheral vessel with the delivery catheter and (2) to deploy the valve accurately across the failing bioprosthetic valve and (3) to remove intact delivery system.</description>
        <time_frame>30 days post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>All enrolled subjects who received the Medtronic CoreValve aortic valve prosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Success.</title>
          <description>The number of subjects in whom technical success was achieved where technical success was defined based on the device functionality as judged by the investigator adressing the ability of the system (1) to access the failing bioprosthetic valve via a peripheral vessel with the delivery catheter and (2) to deploy the valve accurately across the failing bioprosthetic valve and (3) to remove intact delivery system.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from implantation till 12 months follow up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Overall Study</title>
          <description>All enrolled subjects who received the Medtronic CoreValve aortic valve prosthesis</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Documented Mobitz type II AVB II, AVB III</sub_title>
                <counts group_id="E1" events="25" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <description>Any other reported adverse event not associated with the use of the study device were collected without a specific adverse event term</description>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>bleeding event</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological events (CVA, RIND, TIA)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>non structural valve dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical aortic valve replacement</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <description>Any other reported adverse event not associated with the use of the study device were collected without a specific adverse event term</description>
                <counts group_id="E1" events="44" subjects_affected="13" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>bleeding event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>M. Hollander</name_or_title>
      <organization>Medtronic</organization>
      <phone>+31620534428</phone>
      <email>maarten.hollander@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

